Response to "Comments on sirolimus use and risk of cutaneous squamous cell carcinoma (SCC) in solid organ transplant recipients" (SOTRs).
Response to "Comments on sirolimus use and risk of cutaneous squamous cell carcinoma (SCC) in solid organ transplant recipients" (SOTRs).
复制标题
对“关于实体器官移植受者使用西罗莫司和皮肤鳞状细胞癌 (SCC) 风险的评论”(SOTR) 的回应。
DOI：
10.1016/j.jaad.2016.01.063
复制
发表时间：
2022
影响因子：
13.8
通讯作者：
Weisshaar,Dana
中科院分区：
文献类型：
--
作者：
Asgari,MaryamM;Arron,Sarah;Warton,EMargaret;QuesenberryJr,CharlesP;Weisshaar,Dana
致编辑：我们感谢西罗莫司使用与实体器官移植受者（SOTR）皮肤鳞状细胞癌（SCC）风险评论的作者提出了一些重要的问题，即：（1）缺乏剂量信息，（2）缺乏与SCC风险相关的其他药物（硫唑嘌呤除外）的信息，（3）缺乏肿瘤侵袭性和可能不完整病例捕获的信息。我们没有将剂量作为我们模型中的变量，因为在我们的SOTR队列中，给药方案的变异性很小。对于我们的大多数暴露队列（n= 512，88.6%），西罗莫司的平均日剂量在1.0和1.5 mg/d之间，其中n= 45（7.9%）分发的剂量低于1 mg/d; n= 21（3.6%）分发的剂量超过1.5 mg/d。由于缺乏变异性，我们无法在分析中得出有意义的剂量结论。
To the Editor: We thank the authors of the commentary on sirolimus use and risk of cutaneous squamous cell carcinoma (SCC) in solid organ transplant recipients (SOTRs) for raising some important concerns, namely:(1) lack of information on dose,(2) lack of information on other drugs associated with SCC risk (aside from azathioprine), and (3) lack of information on tumor invasiveness and possible incomplete case capture.We did not include dose as a variable in our models because there was very little variability in dosing regimens in our SOTR cohort. The mean daily dose of sirolimus was between 1.0 and 1.5 mg/d for the majority of our exposed cohort (n= 512, 88.6%), with n= 45 (7.9%) dispensed less than 1 mg/d; and n= 21 (3.6%) dispensed more than 1.5 mg/d. Given this lack of variability, we did not have the ability to draw meaningful conclusions about dose in our analyses.